Possible contribution of aminopeptidase N (APN/CD13) to migration and invasion of human osteosarcoma cell lines

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2475-2485

  Liang, Wenqing ^a   Gao, Bo ^b   Xu, Guojian ^a   Weng, Dong ^a   Xie, Minghua ^a   Qian, Yu ^a  

^a SHAOXING PEOPLE S HOSPITAL   (China)

^b 306 HOSPITAL OF PLA   (China)

Author keywords

Aminopeptidase N; Matrix metalloproteinase; Metastasis; Osteosarcoma

Indexed keywords

BESTATIN; LEUCINE; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; OSTEOSARCOMA; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANTIGENS, CD13; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUCINE; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; OSTEOSARCOMA; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84907701405     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2664     Document Type: Article

References (56)

1. Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 152:3-13, 2009.
2. Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, Pappo AS; Soft Tissue Sarcoma Committee of the Children's Oncology Group: Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Eur J Cancer 40:1878-1885, 2004.
3. Cheng YY, Huang L, Lee KM, Li K and Kumta SM: Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 42:410-415, 2004.
4. Cho HJ, Lee TS, Park JB, et al: Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40:1069-1076, 2007.
5. Xin ZF, Kim YK and Jung ST: Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 28:105, 2009.
6. Fan DG, Dai JY, Tang J, et al: Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells. Cell Biol Int 33:1263-1267, 2009.
7. Dass CR, Nadesapillai AP, Robin D, et al: Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 22:643-652, 2005.
8. Wan X, Kim SY, Guenther LM, et al: Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 28:3401-3411, 2009.
9. Haydon RC, Deyrup A, Ishikawa A, et al: Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102:338-342, 2002.
10. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T and Mukai K: Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20:525-529, 2003.
11. Engin F, Bertin T, Ma O, et al: Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 18:1464-1470, 2009.
12. Hughes DP: How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 152:479-496, 2009.
13. Leow PC, Tian Q, Ong ZY, Yang Z and Ee PL: Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/ß-catenin antagonists against human osteosarcoma cells. Invest New Drugs 28:766-782, 2010.
14. Li Y, Zhang J, Ma D, et al: Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. FEBS J 279:2247-2259, 2012.
15. Lin YM, Chang ZL, Liao YY, Chou MC and Tang CH: IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma. Cancer Lett 328:135-143, 2013.
16. Berdiaki A, Datsis GA, Nikitovic D, et al: Parathyroid hormone (PTH) peptides through the regulation of hyaluronan metabolism affect osteosarcoma cell migration. IUBMB Life 62:377-386, 2010.
17. Yang R, Hoang BH, Kubo T, et al: Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 121:943-954, 2007.
18. Dobashi Y, Watanabe H, Matsubara M, et al: Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours. J Pathol 208:44-53, 2006.
19. Niinaka Y, Harada K, Fujimuro M, et al: Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res 70:9483-9493, 2010.
20. Fromigue O, Hamidouche Z, Vaudin P, et al: CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res 26:1533-1542, 2011.
21. Bauvois B: Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23:317-329, 2004.
22. Carl-McGrath S, Lendeckel U, Ebert M and Röcken C: Ectopeptidases in tumour biology: a review. Histol Histopathol 21:1339-1353, 2006.
23. Hitzerd SM, Verbrugge SE, Ossenkoppele G, Jansen G and Peters GJ: Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids 46:793-808, 2014.
24. Kido A, Krueger S, Haeckel C and Roessner A: Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines. Clin Exp Metastasis 17:857-863, 1999.
25. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I and Tsuruo T: Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis 13:337-344, 1995.
26. Kehlen A, Lendeckel U, Dralle H, Langner J and Hoang-Vu C: Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 63:8500-8506, 2003.
27. Petrovic N, Schacke W, Gahagan JR, et al: CD13/APN regulates endothelial invasion and filopodia formation. Blood 110:142-150, 2007.
28. Hong DY, Lee BJ, Lee JC, Choi JS, Wang SG and Ro JH: Expression of VEGF, HGF, IL-6, IL-8, MMP-9, telomerase in peripheral blood of patients with head and neck squamous cell carcinoma. Clin Exp Otorhinolaryngol 2:186-192, 2009.
29. Loo WT, Sasano H and Chow LW: Pro-inflammatory cytokine, matrix metalloproteinases and TIMP-1 are involved in wound healing after mastectomy in invasive breast cancer patients. Biomed Pharmacother 61:548-552, 2007.
30. Güllü IH, Kurdoʇlu M and Akalin I: The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. Br J Cancer 82:249, 2000.
31. Mizutani K, Kofuji K and Shirouzu K: The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg Today 30:614-621, 2000.
32. Korpi JT, Hagström J, Lehtonen N, et al: Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol 20: el8-e22, 2011.
33. Ferrari C, Benassi S, Ponticelli F, et al: Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand 75:487-491, 2004.
34. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG and Taylor S: Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br 84:706-711, 2002.
35. Himelstein BP, Asada N, Carlton MR and Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 31:471-474, 1998.
36. Bellido T, O'Brien CA, Roberson PK and Manolagas SC: Transcriptional activation of the p21 (WAFl, CIPl, SDIl) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273:21137-21144, 1998.
37. Franchimont N, Gangji V, Durant D and Canalis E: Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. Endocrinology 138:5248-5255, 1997.
38. Jilka RL, Weinstein RS, Bellido T, Parfitt AM and Manolagas SC: Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13:793-802, 1998.
39. Nishimura R, Moriyama K, Yasukawa K, Mundy GR and YonedaT: Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res 13:777-785, 1998.
40. Kehlen A, Göhring B, Langner J and Riemann D: Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators. Clin Exp Immunol 111:435-441, 1998.
41. Chen YY, Chiang SY, Lin JG, et al: Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int J Oncol 36:1113-1120, 2010.
42. Lin CC, Chen JT, Yang JS, et al: Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9. Oncol Rep 22:1033-1037, 2009.
43. Lai KC, Huang AC, Hsu SC, et al: Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 58:2935-2942, 2010.
44. Liu KC, Huang AC, Wu PP, et al: Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol Rep 26:177-184, 2011.
45. Chiang JH, Yang JS, Ma CY, et al: Danthron, an anthraquinone derivative, induces DNA damage and caspase cascades-mediated apoptosis in SNU-1 human gastric cancer cells through mitochondrial permeability transition pores and Bax-triggered pathways. Chem Res Toxicol 24:20-29, 2011.
46. Wen YF, Yang JS, Kuo SC, et al: Investigation of anti-leukemia molecular mechanism of ITR-284, a carboxamide analog, in leukemia cells and its effects in WEHI-3 leukemia mice. Biochem Pharmacol 79:389-398, 2010.
47. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004, 2005.
48. Qi M and Elion EA: MAP kinase pathways. J Cell Sci 118:3569-3572, 2005.
49. Bond M, Chase AJ, Baker AH and Newby AC: Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 50:556-565, 2001.
50. Bauvois B and Dauzonne D: Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 26:88-130, 2006.
51. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217, 2005.
52. Lo CW, Chen MW, Hsiao M, et al: IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71:424-434, 2011.
53. Tang CH, Chen CF, Chen WM and Fong YC: IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem 286:11056-11066, 2011.
54. Tu B, Du L, Fan QM, Tang Z and Tang TT: STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 325:80-88, 2012.
55. Mina-Osorio P: The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med 14:361-371, 2008.
56. Liao CL, Lai KC, Huang AC, et al: Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem Toxicol 50:1734-1740, 2012.